Okayama Rosai Hospital

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021 · 1.1K citations · Full text

Checkmate 743, Medicine, Pathology +4

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Solange Peters, Arnaud Scherpereel, Robin Cornelissen et al. · Annals of Oncology · 2022 · 250 citations · Full text

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

Noriyuki Yamada, Satoshi Oizumi, Eiki Kikuchi et al. · Cancer Immunology Immunotherapy · 2010 · 170 citations · Full text

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +9

Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma

Yasuhiro Gotô, Keiko Shinjo, Yutaka Kondo et al. · Cancer Research · 2009 · 125 citations

Chromatin, Malignant Pleural Mesothelioma, Epigenetic Change +13

Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma

Takafumi Kubo, Shinichi Toyooka, Kazunori Tsukuda et al. · Clinical Cancer Research · 2011 · 124 citations